Chongqing Pharscin Stock Hits Day Low of CNY 13.10 Amid Price Pressure

Chongqing Pharscin Pharmaceutical Co., Ltd. experienced significant volatility on July 17, 2026, with the stock hitting an intraday low of CNY 13.10, reflecting a decline of 9.37% for the day. This performance starkly contrasts with the China Shanghai Composite, which fell by 3.05% during the same period. Over the past week, Chongqing Pharscin has seen a decrease of 7.19%, while its one-month performance remains positive at 8.85%. However, the stock has struggled over the longer term, with a year-to-date decline of 11.14% and a substantial drop of 24.37% over the past year. The company's market capitalization stands at CNY 3,439 million, categorizing it as a mid-cap entity within the pharmaceuticals and biotechnology sector. Financial metrics indicate challenges, with a return on equity of just 2.47% and a high price-to-book ratio of 1.99. The company has reported a negative net profit growth of 33.77% in the latest half-year results, alongside a significant decline in operating profit over the past five years. These factors contribute to a cautious outlook on the stock's performance in the current market environment.